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Summary
Celiac sprue (also known as celiac disease) is an
inheritable, gluten-induced enteropathy of the upper
small intestine with an estimated prevalence of 0.5%–
1% in most parts of the world. The ubiquitous nature of
food gluten, coupled with inadequate labeling regula-
tions in most countries, constantly poses a threat of
disease exacerbation and relapse for patients. Here,
we demonstrate that a two-enzyme cocktail comprised
of a glutamine-specific cysteine protease (EP-B2) that
functions under gastric conditions and a PEP, which
acts in concert with pancreatic proteases under duo-
denal conditions, is a particularly potent candidate
for celiac sprue therapy. At a gluten:EP-B2:PEP weight
ratio of 75:3:1, grocery store gluten is fully detoxified
within 10 min of simulated duodenal conditions, as
judged by chromatographic analysis, biopsy-derived
T cell proliferation assays, and a commercial anti-
gluten antibody test.
Introduction
Celiac sprue is an inheritable enteropathy of the upper
small intestine that is believed to afflict approximately
1:200 people in most parts of the world [1]. The disease
is characterized by intestinal inflammation, villous atro-
phy, and crypt cell hyperplasia, resulting in a significant
decrease in intestinal wall surface area [2]. This drastic
reduction in surface area in turn triggers impaired nutri-
ent absorption causing complications such as diarrhea,
weight loss, anemia, and bone disorders, to name a few
[3]. The principal environmental trigger has been identi-
fied as gluten from common food grains such as wheat,
barley, and rye [2–4]. Strict exclusion of all forms of die-
tary gluten results in disease remission in most celiac
sprue patients. However, the ubiquitous nature of gluten
coupled with inadequate labeling regulations in most
countries constantly poses a threat of relapse for pa-
tients, thereby lowering their quality of life. Nondietary
*Correspondence: khosla@stanford.edutherapies that allow celiac patients to safely incorporate
low-to-moderate levels of gluten into their daily diet
would therefore be of considerable benefit.
Wheat gluten is a complex mixture of polypeptides
consisting of alcohol-soluble gliadins and alcohol-insol-
uble, disulfide-crosslinked glutenins. The primary struc-
tures of gluten proteins are dominated by proline (15%)
and glutamine (35%) residues [5]. This unique structural
feature, especially the high proline content, makes glu-
ten unusually resistant to gastric and pancreatic prote-
ases [6–9]. As a result, many long peptides (>20-mers)
persist over a considerable length of the small intestinal
lumen and are only partially hydrolyzed by the exopep-
tidases of the intestinal brush border membrane [10].
The inflammatory character of several of these metasta-
ble peptides has been extensively investigated [7, 9–11].
Perhaps most notably, some gliadin peptides are dea-
midated at selected glutamine residues by transglutami-
nase 2 (TG2), which further increases their affinity for
disease-associated HLA DQ2 [11–15]. The resulting
peptide-DQ2 complexes are potent triggers of inflam-
matory Th1 cell proliferation in the gut mucosa of celiac
sprue patients [16]. Similarly, B cell epitopes in gluten
are also comprised of proteolytically resistant proline-
and glutamine-rich sequences [17]. Finally, at least one
proteolytically resistant gliadin peptide is known to elicit
an IL-15-mediated innate immune response in biopsies
from celiac sprue patients [18, 19]. Thus, eliminating
or reducing the luminal concentration of gluten-derived
proline- and glutamine-rich immunotoxic peptides in the
celiac small intestine can be expected to have signifi-
cant therapeutic potential.
A variety of in vitro, in vivo (animal), and ex vivo (hu-
man) experimental approaches have shown that prolyl
endopeptidases (PEPs) can readily cleave proline-rich
gluten peptides, thereby reducing the antigenic burden
of gluten [6–9, 20]. The potential to use PEPs as an oral
enzyme treatment for celiac sprue is appealing because
their pH-activity profile and substrate specificity com-
plement mammalian pancreatic proteases. Each post-
proline cleavage catalyzed by PEP on a metastable
gluten peptide generates two shorter peptides, yielding
one new amino and carboxyl terminus. In addition to
directly reducing the antigenic burden of gluten, both
of these outcomes yield peptides that are suitable sub-
strates for further cleavage at the intestinal surface by
constitutive brush-border aminopeptidases and car-
boxypeptidases. PEP can be readily formulated as an
enteric-coated pill that protects the enzymatic activity
from the harsh conditions of the stomach and rapidly
releases its contents under simulated duodenal condi-
tions [21].
A potential concern is that when administered as an
active enzyme in the duodenum, PEP may not detoxify
gluten fast enough to adequately protect a patient from
multigram quantities of dietary gluten [22, 23]. Preclini-
cal investigation of this potential limitation is hampered
by the absence of a suitable animal model for HLA-
dependent gluten enteropathy or sufficient insight into
the time- and dose-dependence of the pathogenic
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650Table 1. Characterization of Biopsy-Derived Polyclonal T Cell Lines with a Panel of Known Gluten Epitopes at 50 mM Peptide Concentrations
Peptide Sequence P26 TCL 2 P28 TCL 1 P28 TCL 2 P34 TCL 1 P34 TCL 2 P35 TCL 1
Glutenin PFSQQQQPVa — + — + + —
Hor-a 9 analog PFPQPQQQFa ++ ++ + + ++ —
26-mer FLQPQQPFPQQPQQPYPQQPQQPFPQa ++++ +++ ++ ++ +++ +
g IV SQPQQQFPQPQQPQa — ++ — — + ++
g I PQQSFPQQQa — — — — — —
28-mer PFPQPQLPYPQPQLPYPQPQLPYPQPQPa ++++ +++ +++ +++ +++ +
33-mer LQLQPFPQPELPYPQPELPYPQPELPYPQPQPF ++++ +++ +++ +++ +++ +++
a I PFPQPELPY — ++ +++ ++ ++ +
a II PQPELPYPQ ++++ +++ ++ + ++ ++
a III PYPQPELPY — + +++ ++ +++ ++
The peptide sequence and common name are listed. The stimulation index (SI) is the T cell proliferative response in the presence of antigen
divided by the proliferation in the absence of antigen. + SI > 2, ++ SI > 3.5, +++ SI > 5.0, ++++ SI > 7.5.
a Peptide deamidated with recombinant human tissue transglutaminase.response to gluten in a patient. With regards to the latter
option, seminal studies by Shiner and coworkers [24, 25]
and by Marsh and coworkers [26, 27] demonstrated
that: (1) histological and immunological changes are
evident in the upper small intestine of some celiac sprue
patients within 5–12 hr postgluten challenge, but not as
early as 2 hr; and (2) the magnitude of these changes
correlates with gluten dose. With the advent of more
advanced chemical and biological tools (e.g., synthetic
immunotoxic peptides, biopsy derived T cell cultures,
organ culture systems), the kinetics of gluten peptide
transport [28] and recognition by disease-specific cells
[11, 12, 14, 15, 18] can be explored with greater precision;
however, quantitative relationships between these
ex vivo measurements and in vivo pathogenesis is un-
known. Regardless of these uncertainties, it can be as-
sumed that the therapeutic efficacy of an oral enzyme
agent will improve gluten peptide processing by reduc-
ing the time required for a single dosage unit of a thera-
peutic ‘‘glutenase’’ to detoxify multigram quantities of
gluten.
The goal of this study was to devise an effective glu-
tenase for oral therapy of celiac sprue. To this end, we
sought to address two issues. First, we compared the
gluten detoxification ability of two of the most promis-
ing PEP enzymes studied thus far. They include PEPs
from the bacteria Flavobacterium meningosepticum
(FM) and Myxococcus xanthus (MX) [9, 20, 21, 29].
Although neither PEP proved to be clearly superior to
the other at destroying digestively resistant T cell epi-
topes in gluten, FM PEP showed a general improve-
ment over MX PEP especially in targeting the immuno-
dominant aII epitope. Second, we evaluated whether
EP-B2, a recombinant glutamine-specific cysteine pro-
tease from barley, could enhance the detoxification po-
tential of PEP by virtue of its complementary sequence
specificity, chain-length specificity and pH-activity
profile [30]. At a gluten:EP-B2:FM PEP weight ratio of
75:3:1, grocery store gluten was fully detoxified within
10 min of simulated duodenal conditions, as judged
by chromatographic analysis, biopsy-derived T cell
proliferation assays, and a commercial antigluten anti-
body test. Our results suggest that a two-enzyme
cocktail containing FM PEP and EP-B2 would be a dra-
matically superior therapeutic candidate for the treat-
ment of celiac sprue as compared to PEP as a single
agent.Results
Isolation and Characterization of Polyclonal T Cell
Lines from Celiac Sprue Patients
Polyclonal gluten-responsive T cell lines derived from
small intestinal biopsies of celiac sprue patients have
been an invaluable tool for the identification of toxic
gluten epitopes [12–14], as well as quantitative assess-
ment of the gross toxicity of whole gluten digested with
potential supplemental enzyme therapies [9]. In this
study, we isolated six biopsy-derived, gluten-respon-
sive T cell lines from four unrelated patients and charac-
terized the epitope specificity of each line against a
panel of known gluten epitopes (Table 1). Three of the
cell lines from patients #28, #34, and #35 (named P28,
P34, and P35 TCL1, respectively) were obtained by chal-
lenging biopsy samples with chymotrypsin- and human
transglutaminase 2 (TG2)-treated gliadin. Two additional
cell lines, also from patients #28 and #34 (P28 and P34
TCL2, respectively), were obtained by challenging the
biopsies with a highly immunogenic 33-mer peptide from
a2-gliadin (LQLQPFPQPELPYPQPELPYPQPELPYPQP
QPF) [7]. The sixth T cell line was derived from a biopsy
sample from patient #26 (P26 TCL2) by first stimulating
with chymotrypsin- and TG2-treated gliadin, followed
by secondary stimulation with the synthetic 33-mer pep-
tide in the presence of DQ2 homozygous VAVY cells (an
EBV transformed B cell line) used as antigen presenting
cells.
The epitope specificity of these T cell lines highlights
the heterogeneous nature of this disease with respect
to the spectrum of epitope recognition and magnitude
of response. P28 and P34 TCL1 cell lines responded to
most of the a- and g-gliadin peptides tested and repre-
sent the cell lines with the broadest gluten responsive
T cell repertoires. In contrast, the P26 TCL2 cell line re-
sponded nearly exclusively to the immunodominant aII
gliadin epitope. As shown in Table 1, the P26 TCL2 cell
line also showed strong proliferation in the presence of
the epitope-rich 26-mer peptide from g-gliadin [10] at
a concentration of 50 mM. However, at 5 mM peptide con-
centrations, the stimulation index of the 26-mer fell to
1.8, while the stimulation index resulting from aII epitope
challenge remained at around 9.0 and fell below 2.0 only
at the lowest concentration tested (0.05 mM). Further, an
aII-specific T cell clone isolated from P26 TCL2 showed a
similar response toward the 26-mer peptide, confirming
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651Figure 1. Comparison of FM PEP versus MX
PEP in Detoxification of Predigested Gluten
at Three Different Doses
Gluten was digested with the gastric prote-
ase pepsin for 60 min at pH 2.0 followed by
treatment with the pancreatic proteases
trypsin, chymotrypsin, elastase, and car-
boxypeptidase A (TCEC) for 120 min at pH
6.0. The resultant mixture of digestively resis-
tant gluten peptides was then treated with FM
PEP or MX PEP for 30 min at gluten:PEP
weight ratios of 375:1, 75:1, and 15:1. Four
polyclonal T cell lines were used to assess
the net antigenicity of these digests. The
error bars represent the standard deviation
of duplicate measurements.a weak crossreactivity of some aII-specific T cell recep-
tors with g-gliadin epitopes (data not shown). Because
relatively high concentrations of g-gliadin epitopes were
necessary to induce aII-specific T cell proliferation,
P26 TCL2 is a useful probe for assessing the abundance
of the aII epitope in digested whole gluten. It should be
noted that the peptide panel used here is not an exhaus-
tive list of gluten epitopes. There are other known [31]
and putatively unknown epitopes [10] found in gluten
that some of these polyclonal cell lines may recognize.
Comparing the Gluten-Detoxifying Ability of FM PEP
and MX PEP
The polyclonal T cell lines generated and characterized
as above were used to identify the most appropriate
PEP for detoxifying gluten in the duodenum. In earlier
studies, we compared the biochemical and pharmaco-
logical properties of several candidate PEPs [10, 21,
29]. Two PEPs from Flavobacterium meningosepticum
(FM) and Myxococcus xanthus (MX) are among the
most promising therapeutic candidates analyzed to
date on account of their ability to proteolyze long gluten
peptides, their preference for immunodominant T cell
epitopes from a-gliadins, and their relative stability to-
ward pancreatic protease attack. We therefore com-
pared the kinetics of FM PEP- versus MX PEP-mediated
detoxification of predigested gluten under simulated du-
odenal conditions. Food-grade gluten (12 mg/ml) was
first treated with the gastric protease pepsin for 1 hr at
pH 2.0. The pH was then raised to 6.0, and the pancre-
atic proteases trypsin, chymotrypsin, elastase, and car-
boxypeptidase A (TCEC) were added for 2 hr before
being quenched by boiling. The resulting solution of
proteolytically resistant peptides was treated with either
FM or MX PEP at gluten:PEP weight ratios of 375:1, 75:1,
and 15:1 for 30 min. The digests were deamidated with
recombinant human transglutaminase 2 (TG2) and then
used in T cell proliferation assays.
As shown in Figure 1, neither PEP was able to com-
pletely detoxify gluten with respect to all T cell lines
tested. Nevertheless, in general, FM PEP treatment re-
sulted in lower T cell proliferation than MX PEP. Further,
FM PEP was approximately 25 times faster at eliminat-ing the immunodominant aII epitope than MX PEP as
judged by the P26 TCL 2 T cell line. Therefore, FM PEP
was selected for further evaluation as part of a two-
enzyme cocktail.
EP-B2 Significantly Enhances Gluten Digestion
under Simulated Gastric Conditions
In addition to proline residues, immunotoxic gluten pep-
tides have high glutamine content (30%–35%) [5]. In a
companion report in this issue of Chemistry & Biology
[30], we have therefore expressed, purified, and bio-
chemically characterized the zymogen form of a gluta-
mine-specific cysteine protease from barley, EP-B2
[32]. In addition to its attractive sequence specificity,
proEP-B2 is able to rapidly self-activate from its zymo-
gen form under gastric conditions. The mature enzyme
is highly resistant to pepsin proteolysis and has a desir-
able pH-activity profile (excellent activity in the pH 3–7.5
range) [30]. We therefore anticipated that a two-enzyme
combination agent comprised of EP-B2 and PEP would
accelerate gluten digestion in comparison to either en-
zyme alone, with EP-B2 proteolyzing dietary gluten into
small peptides in the stomach, and the two-enzyme cock-
tail (in conjunction with pancreatic proteases) rapidly
eliminating residual toxicity of gluten in the duodenum.
To investigate the effect of EP-B2 on gluten under
gastric conditions, a high concentration of food-grade
gluten (15 mg/ml; corresponding to a meal of ca. two sli-
ces of bread) was treated either with pepsin alone (25:1
gluten:pepsin) or pepsin supplemented with proEP-B2
(25:1 and 250:1 gluten:EP-B2). These experiments were
performed at a pH of 4.5 to mimic the environment of
a full stomach, although analogous experiments at pH
3 yielded similar results (data not shown). The reactions
were sampled at 10, 30, 45, and 60 min and were
quenched by boiling.
HPLC analysis (Figure 2) of the high-dose EP-B2 di-
gests revealed a dramatic shift toward a shorter peptide
fragment profile when pepsin was supplemented with
EP-B2. The high concentration of long, minimally di-
gested gluten peptides (eluting around 25 min), which
persist in the presence of pepsin alone, is rapidly
reduced within the first 10 min of EP-B2 addition.
Chemistry & Biology
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Effect of EP-B2 on Gastric Digestion of
Gluten
Food-grade gluten was digested with pepsin
alone or pepsin supplemented with EP-B2
(25:1 gluten: EP-B2) at pH 4.5. At various
times, the reaction products were quenched
and analyzed by HPLC with a reverse phase
C18 column. In general, short peptide frag-
ments elute at earlier times than long peptide
fragments. For example, under these HPLC
conditions, representative Pro- and Gln-rich
9-mer, 11-mer, 12-mer, 14-mer, 21-mer, and
28-mer peptides elute at 12.5 min, 18.5 min,
20 min, 21.5 min, 22.5 min, and 22 min,
respectively. Pepsin + EP-B2: blue line, 10
min; red line, 30 min; green line, 45 min; black
line, 60 min; pepsin alone: gray line, 60 min.The immunotoxicity of the reaction products generated
by pepsin alone or pepsin plus EP-B2 was compared via
T cell proliferation assays with the aforementioned
gluten-responsive polyclonal T cell lines. After 10 min,
both high- (25:1 gluten:EP-B2) and low- (250:1 glute-
n:EP-B2) dose EP-B2 digests showed a higher inflam-
matory capacity than gluten treated with pepsin alone
(Figure 3). In contrast, after 60 min, gluten was partially
detoxified by pepsin plus high-dose EP-B2, whereas
the T cell reactivity of gluten treated with pepsin alone
or pepsin plus low-dose EP-B2 continued to increase.
Since some proteolysis is required to convert gluten
polypeptides into shorter, bona fide antigenic peptides,
these results suggest that EP-B2 can greatly accelerate
the sluggish pepsin-catalyzed gastric digestion of glu-
ten. However, notwithstanding the remarkable ability
of this enzyme to simplify the texture and chemistry of
gluten before food arrives in the primary affected organ,
the data suggests that EP-B2 monotherapy may be in-
sufficient for a majority of celiac sprue patients.
Synergistic Action of EP-B2 and FM PEP in a Potent
Two-Enzyme Glutenase
To investigate the synergistic potential of the comple-
mentary chain-length tolerance, sequence specificity,
and pH-activity profiles of EP-B2 and FM PEP, the kinet-
ics of gluten detoxification under simulated duodenal
conditions was investigated over a period of 60 min.
For this, 15 mg/ml food-grade gluten was pretreatedwith pepsin alone or in combination with EP-B2 (25:1
gluten:EP-B2). The pH was then raised to 6.0, and phys-
iological quantities of the pancreatic enzymes trypsin,
chymotrypsin, elastase, and carboxypeptidase A (TCEC)
with or without supplementation of FM PEP (75:1 glu-
ten:FM PEP) were added. Samples collected after 0,
10, 30, and 60 min were analyzed via HPLC, proliferation
assays with all six gluten-responsive polyclonal T cell
lines, and a widely used antibody-based field test for
measuring gluten content in everyday dietary products
[33].
Remarkably, gluten treated with pepsin plus EP-B2
followed by pancreatic proteases plus FM PEP was
completely nontoxic within 10 min exposure to the sim-
ulated duodenal environment (Figure 4A, see Supple-
mental Data for complete time-course data). To verify
the complete detoxification observed with the two-en-
zyme combination, samples were titrated in T cell prolif-
eration assays up to a high concentration of 1.5 mg/ml
residual gluten. (The EC50 of gluten treated with pepsin
plus pancreatic enzymes was <0.1 mg/ml for all lines
tested.) Indeed, although residual antigenicity could be
detected at the highest concentrations in samples ex-
posed to either enzyme alone, the two-enzyme combi-
nation showed no T cell proliferative capacity at all con-
centrations tested (Figure 5). HPLC analysis of each
sample confirmed the highly synergistic effect of EP-
B2 and FM PEP on gluten digestion (Figure 4B, see Sup-
plemental Data for HPLC data on dose optimization).
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with a commercially available ‘‘gluten stick’’ test de-
signed to recognize a common gluten pentapeptide
sequence, QXP(W/F)P, in everyday food products [34].
Whereas the digest supplemented with FM PEP for
60 min tested positive for the presence of gluten at
200 ng/ml, the digest pretreated with EP-B2 for 60 min
followed by pancreatic proteases for 10 min did not
give a signal at all concentrations tested (up to
1,400,000 ng/ml) (Figure 6). Since this test can detect
gluten down to 2 ppm [33], the glutenase-treated sam-
ples described here appear to have been completely de-
toxified as judged by both T cell and antibody reactivity.
Discussion
Celiac sprue is a widespread but severely underdiag-
nosed disease in which the major environmental (wheat
Figure 3. Kinetic Advantage Provided by EP-B2 Supplementation
for Gluten Detoxification under Simulated Gastric Conditions
Gluten was digested with pepsin alone or supplemented with EP-
B2 at 25:1 or 250:1 gluten:EP-B2 doses. T cell proliferation experi-
ments were used to assess the antigenicity of the resultant
peptides after 10 and 60 min of digestion. A stimulation index of
1 indicates background levels of T cell proliferation and is denoted
with a horizontal line. The error bars represent the standard devia-
tion of duplicate measurements.gluten) and genetic (HLA DQ2) factors have both been
identified [2, 4]. Yet, the only current treatment remains
a strict life-long exclusion of wheat-, barley-, and rye-
containing foods from the diet of celiac sprue patients.
As a result of rapidly growing knowledge regarding the
molecular basis of this disease [4], several therapeutic
approaches can be envisioned [35]. Proteolytic detoxifi-
cation of gluten in the patient’s gastrointestinal tract
represents an especially attractive option because of
both general safety considerations as well as the likeli-
hood that if proven clinically effective, an oral glutenase
agent would complement other therapies designed to
render the patient less susceptible to gluten-mediated
inflammation and enteropathy.
Guided by the primary structure of gluten, we have de-
vised a two-enzyme glutenase to treat celiac sprue. By
combining the glutamine-specific endoprotease EP-B2
with the well-characterized proline-specific endopro-
tease FM PEP, we have demonstrated rapid and com-
plete abrogation of the immunotoxicity of grocery-store
gluten, as measured by chromatographic analysis, pa-
tient-derived T cell assays, and a widely used antibody
test for measuring gluten content in commercial food
products. Not only did EP-B2 directly reduce the anti-
genic burden of gluten as indicated by T cell proliferation
assays, but it also created better substrates for FM PEP,
which prefers shorter peptides. Indeed, at a dose of 75:1
gluten:FM PEP, all gluten antigenicity was destroyed
within 10 min by the addition of pancreatic proteases
supplemented with FM PEP under simulated duodenal
conditions following treatment with EP-B2 and pepsin
under simulated gastric conditions.
Earlier studies by Marti et al. [9] demonstrated that FM
PEP alone was able to reduce the T cell immunotoxicity
of grocery store gluten that had been pretreated with
pepsin followed by pancreatic proteases in 12 out of
the 14 cell lines tested. These results were further vali-
dated by Pyle et al. [20], who showed that food-grade
gluten that had been pretreated with FM PEP did not in-
duce malabsorption in more than 50% of the patients
who were adversely affected by vehicle-treated gluten.
Thus, an enteric-coated form of FM PEP, which is pro-
tected from gastric inactivation and released in the duo-
denum [21], could provide clinical benefit by increasing
the (yet to be determined) no-observed-adverse-effect
level (NOAEL) of gluten in the majority of celiac sprue pa-
tients. However, the practical scope of FM PEP mono-
therapy will likely be limited by both the magnitude of
this NOAEL increase as well as the percentage of pa-
tients that respond favorably to reasonable doses of
the enzyme. In this study, we have therefore attempted
to rationally design a glutenase therapy that could dra-
matically increase the NOAEL of gluten by combining
two enzymes that complement each other with respect
to sequence specificity and their ability to act in different
locations of the gastrointestinal tract. Not only would
this dual enzyme therapy allow celiac sprue patients to
safely ingest larger quantities of gluten than FM PEP
alone, but it may also be a more broadly applicable treat-
ment for the disease. Although this therapy may not
provide patients with a completely unrestricted diet, it
should greatly enhance their dietary freedom.
Under kinetically demanding conditions where FM
PEP monotherapy only had a modest effect in reducing
Chemistry & Biology
654Figure 4. Detoxification of Food-Grade Gluten using the Two-Enzyme Glutenase
Gluten was digested with pepsin alone (P) or pepsin supplemented with EP-B2 (25:1 gluten:EP-B2) for 60 min, followed by treatment with tryp-
sin, chymotrypsin, elastase, and carboxypeptidase A (TCEC) with or without FM PEP (75:1 gluten:FM PEP) for 10 min. (A) Antigen content of
these digests were measured by T cell proliferation assays, with a stimulation index of 1 (denoted with a horizontal line) indicating background
levels of proliferation. (B) Reverse-phase HPLC analysis of the individual and combined effects of EP-B2 and FM PEP on gluten digestion. P +
TCEC, blue line; P + (TCEC + FM PEP), red line; (P + EP-B2) + TCEC, green line; (P + EP-B2) + (TCEC + FM PEP), black line. The error bars
represent the standard deviation of duplicate measurements.the antigenicity of gluten, a combination of EP-B2 and
FM PEP completely abolished T cell proliferation in all
cell lines tested (Figure 4A). It should be noted that
in these experiments, EP-B2 and FM PEP were coincu-
bated with appropriate endogenous proteases (pepsin
in the case of EP-B2, and trypsin, chymotrypsin, elas-
tase and carboxypeptidase A in the case of EP-B2 and
PEP). This mimics the in vivo environment by allowing
for crossproteolysis of one protease by another. It
should also be noted that full detoxification by the
two-enzyme glutenase was observed without addition
of intestinal brush border membrane enzymes [6, 9].
The presence of these enteric peptidases is likely to fur-
ther accelerate the rate of gluten detoxification in vivo.
Although assays involving inflammatory T cells are the
primary measures of gluten immunotoxicity in this study,
recent studies have highlighted the potential role of
other immune pathways in celiac sprue pathogenesis
[18, 19, 36, 37]. While this report does not include exper-
iments aimed at directly examining the effect of glute-
nase-treated gluten on the activation of these innate
immune pathways, our HPLC (Figures 2 and 4B) andgluten antibody (Figure 6) results strongly suggest that
the abundance of immunogenic gluten peptides of all
lengths is greatly reduced by glutenase treatment. Fur-
ther testing of this rationally designed glutenase in a clin-
ical setting is therefore warranted.
Significance
Celiac sprue is a prevalent intestinal disorder esti-
mated to affect 1:200 people in many populations
around the world. The only current therapy is the abso-
lute, life-long exclusion of wheat-, rye-, and barley-con-
taining foods from the diet. A nondietary therapy that
would allow patients to ingest moderate levels of these
grains would therefore be of considerable benefit. We
have devised and evaluated a two-enzyme glutenase
consisting of the glutamine-specific endoprotease
EP-B2 and the proline-specific endopeptidase FM
PEP. EP-B2 acts on gluten under gastric conditions,
whereas FM PEP eliminates the residual toxicity of glu-
ten under duodenal conditions. Within 10 min of simu-
lated duodenal conditions, the two-enzyme cocktail at
Combination Enzyme Therapy for Celiac Sprue
655Figure 5. T Cell Assay Titrations Confirming
the Dramatic Reduction in Gluten Antigen
Content using the Two-Enzyme Glutenase
Gluten was digested with pepsin (P) alone or
pepsin supplemented with EP-B2 (25:1 glute-
n:EP-B2) for 60 min, followed by treatment
with trypsin, chymotrypsin, elastase, and car-
boxypeptidase A (TCEC) with or without FM
PEP (75:1 gluten:FM PEP) for 30 min. Gluten
was incubated with DQ2 homozygous antigen
presenting cells (APCs) at the indicated gluten
concentrations before T cells were added.A
P + TCEC;- P + TCEC + FM PEP;: P + EP-
B2 + TCEC;, P + EP-B2 + TCEC + FM PEP.a dose of 75:3:1 gluten:EP-B2:PEP was able to com-
pletely detoxify gluten as judged by a variety of assays.
Our results set the stage for clinical testing of this oral
enzyme agent for a widespread unmet medical need.
Experimental Procedures
Isolation of Polyclonal T Cell Lines from Intestinal Biopsies
Obtained from Celiac Sprue Patients
Small intestinal biopsies from celiac sprue patients were placed im-
mediately into 1 ml HS T cell media (Iscove’s Modified Dulbecco’s
Medium [Gibco, 12440-053] with 15% heat-inactivated human AB
serum [Valley Biomedical, Inc.], 100 U/ml penicillin, and 100 mg/mlstreptomycin [Gibco]) in a 1.5 ml Eppendorf tube. The tube was
placed on ice and transported to the tissue culture laboratory within
20 min. The biopsy was then placed in 1 ml HS T cell media in a
24-well plate containing 1 mg/ml chymotrypsin-digested, tissue
transglutaminase-deamidated gliadin (Sigma-Aldrich) (prepared as
described in [11]) or 10 mg/ml deamidated 33-mer peptide (LQLQPF
PQPELPYPQPELPYPQPELPYPQPQPF) and incubated at 37ºC and
5% CO2 for approximately 20 hr. The biopsy was then extensively
diced with a sterile scalpel, sheared by vigorous pipetting in HS
T cell media, and mashed with a pipet tip against a 70 mm nylon filter
(BD Falcon) in order to separate T cells from larger pieces of unbro-
ken tissue. The recovered cells were counted and plated at 5–10 3
104 biopsy-derived cells per well in the presence of 1–23 105 g-irra-
diated (4000 rads), autologous peripheral blood mononuclear cellsFigure 6. Gluten Digestions Were Analyzed
by a Commercial Antibody-Based Gluten
Detection Test
The sample labeled ‘‘Control’’ is gluten
treated with pepsin (P) for 60 min followed
by trypsin, chymotrypsin, elastase, and car-
boxypeptidase A (TCEC) for 10 min. The
sample labeled ‘‘w/ FM PEP’’ was treated
with P for 60 min followed by TCEC supple-
mented with FM PEP for 60 min. The sample
labeled ‘‘w/ EP-B2’’ was treated with P sup-
plemented with EP-B2 for 60 min followed by
TCEC for 10 min. The blue stripe is an inter-
nal positive control indicating that the stick
worked properly, and the pink stripe indi-
cates the presence of gluten.
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656(PBMCs) in a U-bottom 96-well plate (BD Falcon) containing 200 ml
HS T cell media. The cultures were grown for 14 days with 50 U/ml
IL-2 added on days 1, 3, 5, 8, and 11. For rapidly dividing lines, the
cultures were split 1:2 when the media turned yellow.
For the second and subsequent rounds of stimulation, 1–53 105 T
cells and 25 3 106 g-irradiated (4,000 rads) allogenic PBMCs were
incubated in 25 ml FBS/HS T cell media (IMDM with 10% heat-inac-
tivated fetal bovine serum [Atlanta Biologicals], 2% heat-inactivated
human AB serum, 100 U/ml penicillin, and 100 mg/ml streptomycin)
with 1 ug/ml PHA (Sigma-Aldrich) at 37ºC and 5% CO2 in a 25 cm
2
T-flask (Nunc) standing on end. These cultures were supplemented
with 50 U/ml IL-2 on days 1, 3, 5, 8, and 11, and a media change was
performed on day 5. For peptide specific stimulation, the same pro-
tocol was used except 53 106 DQ2+ homozygous B-LCL VAVY cells
were incubated overnight with the peptide of interest (1 mg/ml glia-
din digest or 10 mg/ml peptide) on day 21 and added to the T cell/
PBMC culture on day 0 in the absence of PHA.
3H-Thymidine T Cell Proliferation Assay
DQ2+ homozygous B-LCL VAVY cells were irradiated with 12,000
rads of g-irradiation and incubated with protein digests or peptides
overnight in FBS/HS T cell media at 2 3 106 cells/ml in 96-well flat
bottom plates. The next day, the volume was doubled to give 1 3
106 VAVY cells/ml, and 50 ml was placed into a U-bottom 96-well
plate. The frozen T cell lines were thawed and allowed to incubate
in FBS/HS T cell media for 1–2 hr. Then, the T cell lines were resus-
pended to a concentration of 1 3 106 cells/ml, and 50 ml was added
to each well of the U-bottom 96-well plate to give 53 104 VAVY cells
and 5 3 104 T cells per well in 100 ml final volume. These cells were
incubated at 37ºC and 5% CO2 for 48 hr at which point 0.5 mCi/well of
[methyl-3H]-Thymidine (Amersham, TRK120) was added. The cells
were incubated for an additional 12–14 hr, and incorporated thymi-
dine was collected on a filter mat (Wallac, 1205-401) with a Tomtec
cell harvester and counted with a Wallac 1205 Betaplate liquid scin-
tillation counter. All samples were run in duplicate wells and the
stimulation index was calculated as the radioactive counts per min-
ute (CPM) in the presence of the peptide divided by the CPM in the
absence of the peptide.
Digestion of PEP-Treated Gluten
Stock solutions of trypsin/chymotrypsin (50 mg/ml), elastase (5 mg/
ml), and carboxypeptidase A (5 mg/ml) were prepared in 25 mM
Na2HPO4 buffer (pH 6.0). Gluten (150 mg) was suspended in 10 ml
of 0.01 M HCl (pH 2.0) and incubated in the presence of pepsin (Pep-
sin NF powder, 1:10000, 6 mg) for 1 hr at 37ºC. Thereafter, 35 mg of
Na2HPO4 was added, and the pH adjusted to 6.0 by addition of 1 M
NaOH or 1 M HCl. Aliquots of 1000 ml of this suspension were placed
into 1.5 ml Eppendorf tubes. The aliquots were then supplemented
with trypsin/chymotrypsin (7.8 ml), elastase (15.6 ml), and carboxy-
peptidase A (15.6 ml) stock solutions. The final concentrations of
pancreatic enzymes in the digest were as follows: 0.375 mg/ml tryp-
sin and chymotrypsin, 0.075 mg/ml elastase, and 0.075 mg carboxy-
peptidase A. The samples were incubated at 37ºC for 120 min and
immediately heat deactivated at 95ºC for >5 min. This PTCEC-
digested gluten was then used as the starting material for the PEP
digestions.
For the PEP digestions, three cases (low, medium, and high en-
zyme level) were evaluated for both enzymes. These cases were de-
fined as 0.2, 1.0, and 5.0 PEP activity units (U) per mg gluten, where
one U is defined as the hydrolysis of 1 mmol of Z-Gly-Pro-p-Nitroani-
lide per min at pH 7.5 and 37ºC (extinction coefficient 8.8 cm2/mmol
at 410 nm). Both enzymes were concentrated prior to use to achieve
greater than 320 activity units per ml. The PTCEC-digested gluten
(200 ml) and a specified amount of 25 mM Na2HPO4 buffer (pH 6.0)
were added to an Eppendorf tube and incubated at 37ºC for approx-
imately 5 min. After this incubation, the specified amount of PEP en-
zyme was added and the final mixture was incubated at 37ºC for 5,
15, or 30 min. The 25 mM Na2HPO4 buffer amount was adjusted to
maintain a constant final volume of 243 ml (and a gluten concentra-
tion of approximately 11.9 mg/ml). At the specified time, the samples
were heat deactivated at 95ºC for >5 min. The samples were centri-
fuged for 10 min at 13,400 3 g and deamidated with recombinant
TG2 prior to performing the T cell assay.Kinetic Analysis of EP-B2 Digestion of Gluten under
Gastric Conditions
Whole gluten (15 mg/ml) was digested under mock gastric condi-
tions (pH 3.0 and 4.5 at 37ºC) by 0.6 mg/ml pepsin or by 0.6 mg/ml
pepsin supplemented with either 0.6 mg/ml proEP-B2 or 0.06 mg/ml
proEP-B2. After 10, 30, 45, and 60 min, samples of the reaction
were taken and boiled to quench. Half of the volume of these sam-
ples were used for HPLC analysis, while the other half was adjusted
to pH 6.0, diluted to 5 mg/ml gluten, deamidated with TG2, and used
in T cell proliferation assays.
Digestion and HPLC Analysis of Gluten Treated with
EP-B2 and/or PEP
Whole gluten (15 mg/ml) was digested under mock gastric condi-
tions (50 mM sodium acetate buffer [pH 4.5] at 37ºC) for 60 min
by 0.6 mg/ml pepsin or by 0.6 mg/ml pepsin supplemented with
0.6 mg/ml proEP-B2. After 60 min, each of these mock gastric reac-
tions was adjusted to pH 6.0 by addition of 50 mM Na2HPO4 (final
concentration) and intestinal proteases (0.375 mg/ml trypsin, 0.375
mg/ml chymotrypsin, 0.075 mg/ml elastase, 0.075 mg/ml carboxy-
peptidase A), or intestinal proteases supplemented with 12.5 U/ml
FM PEP were added, followed by further incubation under mock in-
testinal conditions (pH 6 at 37ºC). At designated time points, reac-
tions were stopped by boiling for 10 min. Quenched digests were
clarified by centrifugation for 10 min at 9,300 3 g.
A portion of each sample supernatant was diluted into HPLC sol-
vent A (5% acetonitrile, 0.1% TFA) with an internal standard (TAME)
and analyzed on HPLC with a C18 reversed phase column by using
a water-acetonitrile gradient containing 0.1% (v/v) TFA. A second
portion of each sample supernatant from the quenched gluten
digests was deamidated with recombinant TG2 and analyzed by
T cell proliferation assays.
EP-B2/FM PEP Dose-Ranging Experiments
Gluten (15 mg/ml) was digested under mock gastric conditions in 20
mM acetate buffer (pH 4.5) for 10 or 30 min with pepsin(0.6 mg/ml)
in the presence or absence of EP-B2 at 10:1, 30:1, or 100:1 gluten:
EP-B2 weight ratios. The pH was then adjusted to 6.0 by adding
Na2HPO4, and pancreatic enzymes (0.375 mg/ml trypsin and chymo-
trypsin, 0.075 mg/ml elastase, and 0.075 mg carboxypeptidase A)
were added in the presence or absence of FM PEP at 24:1, 80:1,
and 267:1 gluten:PEP weight ratios. At the indicated time points,
a 200 ml aliquot was taken from the digestion and boiled to quench
the enzymes. The samples were run on HPLC by using a C18 reverse
phase column with an internal standard (TAME).
Gluten Antibody Test
The assay was a modification of the instructions provided by the
manufacturer (RIDA QUICK Gliadin, R-Biopharm). Gluten digests
were diluted to ten times the indicated concentrations in PBS, and
50 ml of the diluted samples were added to 450 ml of the dilution
buffer provided by the manufacturer. The test sticks were dipped
into the 500 ml solution and allowed to sit for 5 min before being
removed and allowed to air dry.
Peptide and Digest Deamidation
Gluten peptides and digests were treated with 30 mg/ml recombinant
human tissue transglutaminase in the presence of 2.5 mM CaCl2 for
2 hr at 37ºC. The reaction tubes were centrifuged for 2 min at 13,000
rpm to pellet insoluble material and frozen at220ºC until use in T cell
proliferation assays.
Production and Purification of Recombinant Enzymes
FM PEP, MX PEP, EP-B2, and TG2
All recombinant enzymes were made and purified as previously
described [29, 30, 38].
Peptide Synthesis
Peptides were synthesized by Boc/HBTU chemistry as previously
described [39].
Supplemental Data
Supplemental Data include additional time- and dose-dependent
gluten proteolysis data showing the benefit provided by EP-B2
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657and FM PEP supplementation and are available at http://www.
chembiol.com/cgi/content/full/13/6/649/DC1/.
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